179 related articles for article (PubMed ID: 30390073)
1. p53-dependent autophagic degradation of TET2 modulates cancer therapeutic resistance.
Zhang J; Tan P; Guo L; Gong J; Ma J; Li J; Lee M; Fang S; Jing J; Johnson G; Sun D; Cao WM; Dashwood R; Han L; Zhou Y; Dong WG; Huang Y
Oncogene; 2019 Mar; 38(11):1905-1919. PubMed ID: 30390073
[TBL] [Abstract][Full Text] [Related]
2. PML Recruits TET2 to Regulate DNA Modification and Cell Proliferation in Response to Chemotherapeutic Agent.
Song C; Wang L; Wu X; Wang K; Xie D; Xiao Q; Li S; Jiang K; Liao L; Yates JR; Lee JD; Yang Q
Cancer Res; 2018 May; 78(10):2475-2489. PubMed ID: 29735542
[TBL] [Abstract][Full Text] [Related]
3. TET2 controls chemoresistant slow-cycling cancer cell survival and tumor recurrence.
Puig I; Tenbaum SP; Chicote I; Arqués O; Martínez-Quintanilla J; Cuesta-Borrás E; Ramírez L; Gonzalo P; Soto A; Aguilar S; Eguizabal C; Caratù G; Prat A; Argilés G; Landolfi S; Casanovas O; Serra V; Villanueva A; Arroyo AG; Terracciano L; Nuciforo P; Seoane J; Recio JA; Vivancos A; Dienstmann R; Tabernero J; Palmer HG
J Clin Invest; 2018 Aug; 128(9):3887-3905. PubMed ID: 29944140
[TBL] [Abstract][Full Text] [Related]
4. TET2 and DNMT3A mutations and exceptional response to 4'-thio-2'-deoxycytidine in human solid tumor models.
Yang SX; Hollingshead M; Rubinstein L; Nguyen D; Larenjeira ABA; Kinders RJ; Difilippantonio M; Doroshow JH
J Hematol Oncol; 2021 May; 14(1):83. PubMed ID: 34039392
[TBL] [Abstract][Full Text] [Related]
5. P53-mediated upregulation of DcR1 impairs oxaliplatin/TRAIL-induced synergistic anti-tumour potential in colon cancer cells.
Toscano F; Fajoui ZE; Gay F; Lalaoui N; Parmentier B; Chayvialle JA; Scoazec JY; Micheau O; Abello J; Saurin JC
Oncogene; 2008 Jul; 27(30):4161-71. PubMed ID: 18345033
[TBL] [Abstract][Full Text] [Related]
6. p53-Dependent PUMA to DRAM antagonistic interplay as a key molecular switch in cell-fate decision in normal/high glucose conditions.
Garufi A; Pistritto G; Baldari S; Toietta G; Cirone M; D'Orazi G
J Exp Clin Cancer Res; 2017 Sep; 36(1):126. PubMed ID: 28893313
[TBL] [Abstract][Full Text] [Related]
7. PHF2 histone demethylase acts as a tumor suppressor in association with p53 in cancer.
Lee KH; Park JW; Sung HS; Choi YJ; Kim WH; Lee HS; Chung HJ; Shin HW; Cho CH; Kim TY; Li SH; Youn HD; Kim SJ; Chun YS
Oncogene; 2015 May; 34(22):2897-909. PubMed ID: 25043306
[TBL] [Abstract][Full Text] [Related]
8. miR-338-3p confers 5-fluorouracil resistance in p53 mutant colon cancer cells by targeting the mammalian target of rapamycin.
Han J; Li J; Tang K; Zhang H; Guo B; Hou N; Huang C
Exp Cell Res; 2017 Nov; 360(2):328-336. PubMed ID: 28928082
[TBL] [Abstract][Full Text] [Related]
9. MEK5/ERK5 signaling inhibition increases colon cancer cell sensitivity to 5-fluorouracil through a p53-dependent mechanism.
Pereira DM; Simões AE; Gomes SE; Castro RE; Carvalho T; Rodrigues CM; Borralho PM
Oncotarget; 2016 Jun; 7(23):34322-40. PubMed ID: 27144434
[TBL] [Abstract][Full Text] [Related]
10. HMGB1 represses the anti-cancer activity of sunitinib by governing TP53 autophagic degradation via its nucleus-to-cytoplasm transport.
Luo P; Xu Z; Li G; Yan H; Zhu Y; Zhu H; Ma S; Yang B; He Q
Autophagy; 2018; 14(12):2155-2170. PubMed ID: 30205729
[TBL] [Abstract][Full Text] [Related]
11. Tet methylcytosine dioxygenase 2 inhibits atherosclerosis via upregulation of autophagy in ApoE-/- mice.
Peng J; Yang Q; Li AF; Li RQ; Wang Z; Liu LS; Ren Z; Zheng XL; Tang XQ; Li GH; Tang ZH; Jiang ZS; Wei DH
Oncotarget; 2016 Nov; 7(47):76423-76436. PubMed ID: 27821816
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of autophagy exerts anti-colon cancer effects via apoptosis induced by p53 activation and ER stress.
Sakitani K; Hirata Y; Hikiba Y; Hayakawa Y; Ihara S; Suzuki H; Suzuki N; Serizawa T; Kinoshita H; Sakamoto K; Nakagawa H; Tateishi K; Maeda S; Ikenoue T; Kawazu S; Koike K
BMC Cancer; 2015 Oct; 15():795. PubMed ID: 26496833
[TBL] [Abstract][Full Text] [Related]
13. DNA mismatch repair and p53 function are major determinants of the rate of development of cisplatin resistance.
Lin X; Howell SB
Mol Cancer Ther; 2006 May; 5(5):1239-47. PubMed ID: 16731756
[TBL] [Abstract][Full Text] [Related]
14. Cisplatin in Combination with MDM2 Inhibition Downregulates Rad51 Recombinase in a Bimodal Manner to Inhibit Homologous Recombination and Augment Tumor Cell Kill.
Xie X; He G; Siddik ZH
Mol Pharmacol; 2020 Apr; 97(4):237-249. PubMed ID: 32063580
[TBL] [Abstract][Full Text] [Related]
15. The dual role of mutant p53 protein in chemosensitivity of human cancers.
Mueller H; Eppenberger U
Anticancer Res; 1996; 16(6B):3845-8. PubMed ID: 9042268
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of GSK3B bypass drug resistance of p53-null colon carcinomas by enabling necroptosis in response to chemotherapy.
Grassilli E; Narloch R; Federzoni E; Ianzano L; Pisano F; Giovannoni R; Romano G; Masiero L; Leone BE; Bonin S; Donada M; Stanta G; Helin K; Lavitrano M
Clin Cancer Res; 2013 Jul; 19(14):3820-31. PubMed ID: 23729362
[TBL] [Abstract][Full Text] [Related]
17. PRIMA-1 induces autophagy in cancer cells carrying mutant or wild type p53.
Russo D; Ottaggio L; Foggetti G; Masini M; Masiello P; Fronza G; Menichini P
Biochim Biophys Acta; 2013 Aug; 1833(8):1904-13. PubMed ID: 23545415
[TBL] [Abstract][Full Text] [Related]
18. Resistance of colon cancer cells to long-term 5-fluorouracil exposure is correlated to the relative level of Bcl-2 and Bcl-X(L) in addition to Bax and p53 status.
Violette S; Poulain L; Dussaulx E; Pepin D; Faussat AM; Chambaz J; Lacorte JM; Staedel C; Lesuffleur T
Int J Cancer; 2002 Apr; 98(4):498-504. PubMed ID: 11920608
[TBL] [Abstract][Full Text] [Related]
19. Mutant p53 drives cancer chemotherapy resistance due to loss of function on activating transcription of PUMA.
Huang Y; Liu N; Liu J; Liu Y; Zhang C; Long S; Luo G; Zhang L; Zhang Y
Cell Cycle; 2019 Dec; 18(24):3442-3455. PubMed ID: 31726940
[No Abstract] [Full Text] [Related]
20. G9a stimulates CRC growth by inducing p53 Lys373 dimethylation-dependent activation of
Zhang J; Wang Y; Shen Y; He P; Ding J; Chen Y
Theranostics; 2018; 8(10):2884-2895. PubMed ID: 29774081
[No Abstract] [Full Text] [Related]
[Next] [New Search]
